Drug-drug interactions potential of icariin and its intestinal metabolites via inhibition of intestinal UDP-glucuronosyltransferases

Evidence-based Complementary and Alternative Medicine

Volumn 2012, Issue , 2012, Pages

  Cao, Yun Feng ^a,b   He, Rong Rong ^c   Cao, Jun ^d   Chen, Jian Xing ^a   Huang, Ting ^a   Liu, Yong ^b  

^a SHANGHAI INSTITUTE OF PLANNED PARENTHOOD RESEARCH   (China)

^b DALIAN INSTITUTE OF CHEMICAL PHYSICS   (China)

^c JINAN UNIVERSITY   (China)

^d DALIAN MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

DRUG METABOLITE; GLUCURONOSYLTRANSFERASE 1A3; GLUCURONOSYLTRANSFERASE 1A4; GLUCURONOSYLTRANSFERASE 1A7; GLUCURONOSYLTRANSFERASE 1A9; GLUCURONOSYLTRANSFERASE 2B7; ICARIIN; ICARISIDE I; ICARISIDE II; ICARITIN; RECOMBINANT ENZYME; UNCLASSIFIED DRUG;

ARTICLE; CONTROLLED STUDY; DRUG EFFECT; DRUG STRUCTURE; DRUG TISSUE LEVEL; ENZYME ACTIVITY; ENZYME INHIBITION; GLUCURONIDATION; HUMAN; HUMAN EXPERIMENT; IC 50; METABOLITE; PREDICTION; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS;

EID: 84868672788     PISSN: 1741427X     EISSN: 17414288     Source Type: Journal    
DOI: 10.1155/2012/395912     Document Type: Article

References (32)

1. Wu H., Lien E. J., Lien L. L., Chemical and pharmacological investigations of Epimedium species: a survey. Progress in Drug Research 2003 60 1 57 2-s2.0-0038748335 (Pubitemid 36538112)
2. Kim J. H., Mun Y. J., Im S. J., Han J. H., Lee H. S., Woo W. H., Effects of the aqueous extract of Epimedii Herba on the antibody responses in mice. International Immunopharmacology 2001 1 5 935 944 2-s2.0-0035075267 10.1016/S1567-5769(01)00030-3 (Pubitemid 32285434)
3. Ning H., Xin Z. C., Lin G., Banie L., Lue T. F., Lin C. S., Effects of icariin on phosphodiesterase-5 activity in vitro and cyclic guanosine monophosphate level in cavernous smooth muscle cells. Urology 2006 68 6 1350 1354 2-s2.0-33845296134 10.1016/j.urology.2006.09.031 (Pubitemid 44880379)
4. Xu H. B., Huang Z. Q., Icariin enhances endothelial nitric-oxide synthase expression on human endothelial cells in vitro. Vascular Pharmacology 2007 47 1 18 24 2-s2.0-34249280557 10.1016/j.vph.2007.03.002 (Pubitemid 46818133)
5. Zhang Z. B., Yang Q. T., The testosterone mimetic properties of icariin. Asian Journal of Andrology 2006 8 5 601 605 2-s2.0-33747619425 10.1111/j.1745-7262.2006.00197.x (Pubitemid 44263434)
6. Wienkers L. C., Heath T. G., Predicting in vivo drug interactions from in vitro drug discovery data. Nature Reviews Drug Discovery 2005 4 10 825 833 2-s2.0-27644596457 10.1038/nrd1851 (Pubitemid 41553963)
7. Liu K. H., Kim M. J., Jeon B. H., Shon J. H., Cha I. J., Cho K. H., Lee S. S., Shin J. G., Inhibition of human cytochrome P450 isoforms and NADPH-CYP reductase in vitro by 15 herbal medicines, including Epimedii herba. Journal of Clinical Pharmacy and Therapeutics 2006 31 1 83 91 2-s2.0-33645126398 10.1111/j.1365-2710.2006.00706.x
8. Jancova P., Anzenbacher P., Anzenbacherova E., Phase II drug metabolizing enzymes. Biomedical Papers 2010 154 2 103 116
9. Williams J. A., Hyland R., Jones B. C., Smith D. A., Hurst S., Goosen T. C., Peterkin V., Koup J. R., Ball S. E., Drug-drug interactions for UDP-glucuronosyltransferase substrates: a pharmacokinetic explanation for typically observed low exposure (AUC 1/AUC) ratios. Drug Metabolism and Disposition 2004 32 11 1201 1208 2-s2.0-6944221357 10.1124/dmd.104.000794 (Pubitemid 39410902)
10. Liu Y., Ramírez J., House L., Ratain M. J., Comparison of the drug-drug interactions potential of erlotinib and gefitinib via inhibition of UDP-glucuronosyltransferases. Drug Metabolism and Disposition 2010 38 1 32 39 2-s2.0-73149090339 10.1124/dmd.109.029660
11. Liu Y., Ramírez J., Ratain M. J., Inhibition of paracetamol glucuronidation by tyrosine kinase inhibitors. British Journal of Clinical Pharmacology 2011 71 6 917 920 2-s2.0-79955877359 10.1111/j.1365-2125.2011. 03911.x
12. Miners J. O., MacKenzie P. I., Knights K. M., The prediction of drug-glucuronidation parameters in humans: UDP-glucuronosyltransferase enzyme-selective substrate and inhibitor probes for reaction phenotyping and in vitroin vivo extrapolation of drug clearance and drug-drug interaction potential. Drug Metabolism Reviews 2010 42 1 196 208 2-s2.0-74549222703 10.3109/03602530903210716
13. Kiang T. K. L., Ensom M. H. H., Chang T. K. H., UDP- glucuronosyltransferases and clinical drug-drug interactions. Pharmacology and Therapeutics 2005 106 1 97 132 2-s2.0-15244342411 10.1016/j.pharmthera.2004.10. 013 (Pubitemid 40386722)
14. Hasegawa H., Proof of the mysterious efficacy of ginseng: basic and clinical trials: metabolic activation of ginsenoside: deglycosylation by intestinal bacteria and esterification with fatty acid. Journal of Pharmacological Sciences 2004 95 2 153 157 2-s2.0-3142621044 10.1254/jphs.FMJ04001X4 (Pubitemid 38899683)
15. Liu Y., Li W., Li P., Deng M. C., Yang S. L., Yang L., The inhibitory effect of intestinal bacterial metabolite of ginsenosides on CYP3A activity. Biological and Pharmaceutical Bulletin 2004 27 10 1555 1560 2-s2.0-18044384071 10.1248/bpb.27.1555 (Pubitemid 41701638)
16. Liu Y., Ma H., Zhang J. W., Deng M. C., Yang L., Influence of ginsenoside Rh1 and F1 on human cytochrome P450 enzymes. Planta Medica 2006 72 2 126 131 2-s2.0-33644553478 10.1055/s-2005-873197 (Pubitemid 43293866)
17. Liu Y., Yang L., Early metabolism evaluation making traditional Chinese medicine effective and safe therapeutics. Journal of Zhejiang University B 2006 7 2 99 106 2-s2.0-33646590264 10.1631/jzus.2006.B0099
18. Liu Y., Zhang J. W., Li W., Ma H., Sun J., Deng M. C., Yang L., Ginsenoside metabolites, rather than naturally occurring ginsenosides, lead to inhibition of human cytochrome P450 enzymes. Toxicological Sciences 2006 91 2 356 364 2-s2.0-33744799726 10.1093/toxsci/kfj164 (Pubitemid 43827288)
19. Wu J. J., Ai C. Z., Liu Y., Interactions between Phytochemicals from traditional Chinese medicines and human cytochrome P450 enzymes. Current Drug Metabolism 2012 13 5 599 614
20. Uchaipichat V., Mackenzie P. I., Elliot D. J., Miners J. O., Selectivity of substrate (trifluoperazine) and inhibitor (amitriptyline, androsterone, canrenoic acid, hecogenin, phenylbutazone, quinidine, quinine, and sulfinpyrazone) probes for human UDP-glucuronosyltransferases. Drug Metabolism and Disposition 2006 34 3 449 456 2-s2.0-33344473930 10.1124/dmd.105.007369 (Pubitemid 43290903)
21. Thummel K. E., Wilkinson G. R., In vitro and in vivo drug interactions involving human CYP3A. Annual Review of Pharmacology and Toxicology 1998 38 389 430 2-s2.0-0031748173 (Pubitemid 28231501)
22. Copeland R. A., Enzymes: A Practical Introduction to Structure, Mechanism, and Data Analysis 2000 New York, NY, USA Wiley
23. Davies B., Morris T., Physiological parameters in laboratory animals and humans. Pharmaceutical Research 1993 10 7 1093 1095 2-s2.0-0027275566 10.1023/A:1018943613122 (Pubitemid 23211439)
24. Ye L., Chen J., Liu S., Pharmacokinetics of icariin in rats. Chinese Pharmaceutical Journal 1999 34 1 33 36 2-s2.0-0033026501 (Pubitemid 29080496)
25. Cai Y., Jia X.-B., Chen Y., Fan C. Y., Huang L. X., Absorption and metabolism of icariin in the in situ single-pass perfused rat intestinal model. Chinese Pharmaceutical Journal 2009 44 13 985 988 2-s2.0-68449085257
26. Xu W., Zhang Y. P., Yang M., Shen Z., Zhang X., Zhang W., Li H., LC-MS/MS method for the simultaneous determination of icariin and its major metabolites in rat plasma. Journal of Pharmaceutical and Biomedical Analysis 2007 45 4 667 672 2-s2.0-35548960004 10.1016/j.jpba.2007.07.007 (Pubitemid 350007943)
27. Shen P., Wong S. P., Yong E. L., Sensitive and rapid method to quantify icaritin and desmethylicaritin in human serum using gas chromatography-mass spectrometry. Journal of Chromatography B 2007 857 1 47 52 2-s2.0-34548398902 10.1016/j.jchromb.2007.06.026 (Pubitemid 47362857)
28. Bjornsson T. D., Callaghan J. T., Einolf H. J., Fischer V., Gan L., Grimm S., Kao J., King S. P., Miwa G., Ni L., Kumar G., McLeod J., Obach R. S., Roberts S., Roe A., Shah A., Snikeris F., Sullivan J. T., Tweedie D., Vega J. M., Walsh J., Wrighton S. A., The conduct of in vitro and in vivo drug-drug interaction studies: a Pharmaceutical Research and Manufacturers of America (PhRMA) perspective. Drug Metabolism and Disposition 2003 31 7 815 832 2-s2.0-10744232330 10.1124/dmd.31.7.815 (Pubitemid 36759050)
29. Nagar S., Remmel R. P., Uridine diphosphoglucuronosyltransferase pharmacogenetics and cancer. Oncogene 2006 25 11 1659 1672 2-s2.0-33645120407 10.1038/sj.onc.1209375
30. Ritter J. K., Intestinal UGTs as potential modifiers of pharmacokinetics and biological responses to drugs and xenobiotics. Expert Opinion on Drug Metabolism and Toxicology 2007 3 1 93 107 2-s2.0-34250329999 10.1517/17425255.3.1.93 (Pubitemid 47307457)
31. Nakamura A., Nakajima M., Yamanaka H., Fujiwara R., Yokoi T., Expression of UGT1A and UGT2B mRNA in human normal tissues and various cell lines. Drug Metabolism and Disposition 2008 36 8 1461 1464 2-s2.0-47949110575 10.1124/dmd.108.021428
32. Ohno S., Nakajin S., Determination of mRNA expression of human UDP-glucuronosyltransferases and application for localization in various human tissues by real-time reverse transcriptase-polymerase chain reaction. Drug Metabolism and Disposition 2009 37 1 32 40 2-s2.0-58149467072 10.1124/dmd.108.023598